Aubry O A, Spangler E A, Schleis S E, Smith A N
Department of Clinical Sciences, Auburn University, Auburn, AL, USA; Southern California Veterinary Specialty Hospital, Irvine, CA, USA.
Vet Comp Oncol. 2014 Mar;12(1):58-66. doi: 10.1111/j.1476-5829.2012.00331.x. Epub 2012 May 11.
This prospective study evaluated the utility of bone marrow aspirates (BMAs) obtained from multiple sites for staging of canine lymphoma (LSA) and mast cell tumours (MCTs). Forty dogs (LSA, n = 24; MCTs, n = 16) were enrolled, but only 33 (82.5%) had diagnostic bone marrow (BM) aspirates obtained from two sites for inclusion in the study. Nineteen dogs with LSA were included, and 6 (31.6%) had BM involvement. Neoplastic lymphocytes were present in BM from both sites in all of these dogs. Fourteen dogs with MCTs were included, and 3 (21.4%) had BM involvement. Neoplastic mast cells were present at both sites in two dogs and at only one site in the third. These results indicate that BMAs from multiple sites may not be needed for accurate staging of canine LSA patients, but more studies evaluating the pattern of BM infiltration in dogs with high-grade MCTs are warranted.
这项前瞻性研究评估了从多个部位获取的骨髓穿刺液（BMA）在犬淋巴瘤（LSA）和肥大细胞瘤（MCT）分期中的效用。纳入了40只犬（LSA，n = 24；MCT，n = 16），但只有33只（82.5%）从两个部位获取了诊断性骨髓（BM）穿刺液以纳入研究。纳入了19只患有LSA的犬，其中6只（31.6%）有骨髓受累。所有这些犬的两个部位的骨髓中均存在肿瘤性淋巴细胞。纳入了14只患有MCT的犬，其中3只（21.4%）有骨髓受累。两只犬的两个部位均存在肿瘤性肥大细胞，第三只犬仅在一个部位存在。这些结果表明，对于犬LSA患者的准确分期可能不需要多个部位的BMA，但需要更多研究来评估高级别MCT犬的骨髓浸润模式。
